ONCAlert | 2018 ASCO Annual Meeting

Design of the NOVA Trial for Ovarian Cancer

Kathleen N. Moore, MD
Published Online: 1:10 AM, Thu March 16, 2017


Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

The NOVA trial aimed to determine whether the PARP inhibitor niraparib improves progression-free survival (PFS), with other endpoints being overall survival, time to first subsequent therapy, chemotherapy free interval, and other quality of life measures.
 

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.